ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth, Report Focuses on Top Companies Analysis By FMI
NEWARK, DE / April 7, 2026 / The global ESR1 mutated metastatic breast cancer diagnostics market is projected to grow from USD 64.61 million in 2025 to USD 92.92 million by 2035, registering a CAGR of 3.7%. Growth is driven by the rising prevalence of ESR1 mutations in metastatic breast cancer patients, increasing adoption of precision medicine, and advancements in...
0 Комментарии 0 Поделились 6 Просмотры 0 предпросмотр
Zepky https://zepky.com